This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2004 Apr;45(4):399-400.

doi: 10.1016/j.eururo.2003.11.027.

T1G3 bladder cancer: conservative management or cystectomy?

Bernard Gattegno

PMID: 15041100
DOI: 10.1016/j.eururo.2003.11.027

Editorial

T1G3 bladder cancer: conservative management or cystectomy?

Bernard Gattegno. Eur Urol. 2004 Apr.

. 2004 Apr;45(4):399-400.

doi: 10.1016/j.eururo.2003.11.027.

Author

Bernard Gattegno

PMID: 15041100
DOI: 10.1016/j.eururo.2003.11.027

No abstract available

PubMed Disclaimer

Comment on

T1G3 bladder tumours: the case for conservative treatment.
Turner W. Turner W. Eur Urol. 2004 Apr;45(4):401-5. doi: 10.1016/j.eururo.2003.11.008. Eur Urol. 2004. PMID: 15041101 Review. No abstract available.
T1G3 bladder tumours: the case for radical cystectomy.
Malavaud B. Malavaud B. Eur Urol. 2004 Apr;45(4):406-10. doi: 10.1016/j.eururo.2003.11.007. Eur Urol. 2004. PMID: 15041102 Review.

Similar articles

Optimal management of high-risk T1G3 bladder cancer: a decision analysis.
Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM. Kulkarni GS, et al. PLoS Med. 2007 Sep;4(9):e284. doi: 10.1371/journal.pmed.0040284. PLoS Med. 2007. PMID: 17896857 Free PMC article.
Optimal management of the T1G3 bladder cancer.
Manoharan M, Soloway MS. Manoharan M, et al. Urol Clin North Am. 2005 May;32(2):133-45. doi: 10.1016/j.ucl.2005.02.002. Urol Clin North Am. 2005. PMID: 15862611 Review.
Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
Weiss C, Wolze C, Engehausen DG, Ott OJ, Krause FS, Schrott KM, Dunst J, Sauer R, Rödel C. Weiss C, et al. J Clin Oncol. 2006 May 20;24(15):2318-24. doi: 10.1200/JCO.2006.05.8149. J Clin Oncol. 2006. PMID: 16710030
Controversial issues and optimal management of stage T1G3 bladder cancer.
Metwalli AR, Kamat AM. Metwalli AR, et al. Expert Rev Anticancer Ther. 2006 Aug;6(8):1283-94. doi: 10.1586/14737140.6.8.1283. Expert Rev Anticancer Ther. 2006. PMID: 16925494 Review.
[Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?].
Denzinger S, Burger M, Fritsche HM, Ganzer R, Blana A, Wieland WF, Otto W. Denzinger S, et al. Aktuelle Urol. 2008 Jan;39(1):58-61; discussion 62-3. doi: 10.1055/s-2007-980147. Aktuelle Urol. 2008. PMID: 18228189 German.

See all similar articles

Cited by

T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.
De Berardinis E, Busetto GM, Antonini G, Giovannone R, Gentile V. De Berardinis E, et al. Int Urol Nephrol. 2011 Dec;43(4):1047-57. doi: 10.1007/s11255-011-9941-x. Epub 2011 Mar 29. Int Urol Nephrol. 2011. PMID: 21442469

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information